ERBB2 and breast carcinoma: This possibility is partially confirmed in our experiment in that when Her-2 is inhibited by way of therapeutic Her-2 inhibitor and CLDN9 is reduced by genetic knockdown, we were able to sensitize the otherwise resistant Her-2-positive breast cancer to chemodrugs.